Despite growing interest in the hematopoietic effects of SGLT2 inhibitors, no comprehensive systematic review has specifically evaluated the impact of dapagliflozin on anemia outcomes across different patient populations, particularly comparing effects in patients with and without heart failure. This evidence concerns the gene SLC5A2 and heart failure.